← Back to Search

Other

Red-light Therapy for Near-sightedness

N/A
Recruiting
Led By Julius Oatts, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial showed that 3 minutes of low-level red-light technology twice a day can control 87.7% of myopia progression and 76.8% of axial length elongation. This could be a potential global solution for myopia control.

Who is the study for?
This trial is for kids aged 8-13 with near-sightedness (myopia) between -1.00 and -5.00 diopters, less than 1.50 diopters of anisometropia, and up to 2.50 diopters of astigmatism who speak English and have good corrected vision. It's not for those with eye abnormalities, previous myopia treatments, or severe disabilities.Check my eligibility
What is being tested?
The study tests a low-level red-light therapy device as a treatment for myopia in children from diverse backgrounds by having them undergo short light sessions twice daily to see if it can control the progression of their near-sightedness effectively.See study design
What are the potential side effects?
While specific side effects are not listed here, similar light therapies have been associated with minimal risks such as mild discomfort or temporary visual disturbances.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Axial Length (AL) (mm) at Baseline
Axial Length (AL) (mm) at Month 1
Axial Length (AL) (mm) at Month 3
+2 more
Secondary outcome measures
Anterior Chamber Depth (ACD) at Baseline
Anterior Chamber Depth (ACD) at Month 1
Anterior Chamber Depth (ACD) at Month 3
+32 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Low Level Red Light Treatment ArmExperimental Treatment1 Intervention
On top of wearing single vision spectacles, subjects in the intervention group will receive low-level red light treatment twice a day from Monday to Friday, with each treatment lasting for 3 minutes at a minimal interval of 4 hours.
Group II: Control Treatment ArmActive Control1 Intervention
Subjects in the control group will wear single vision spectacles.

Find a Location

Who is running the clinical trial?

University of MelbourneOTHER
167 Previous Clinical Trials
1,288,210 Total Patients Enrolled
University of California, San FranciscoLead Sponsor
2,507 Previous Clinical Trials
15,238,485 Total Patients Enrolled
Julius Oatts, MDPrincipal InvestigatorUniversity of California, San Francisco
3 Previous Clinical Trials
190 Total Patients Enrolled

Media Library

Low-level Red Light Therapy Device (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05606237 — N/A
Near-sightedness Research Study Groups: Low Level Red Light Treatment Arm, Control Treatment Arm
Near-sightedness Clinical Trial 2023: Low-level Red Light Therapy Device Highlights & Side Effects. Trial Name: NCT05606237 — N/A
Low-level Red Light Therapy Device (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05606237 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What qualifications do potential participants need to meet for this trial?

"This trial is welcoming 90 candidates between the ages of 8 and 13 who suffer from myopia."

Answered by AI

Is eligibility for this research extending to octogenarians?

"This medical trial has established age limits with 8 being the youngest acceptable participant and 13 representing the oldest."

Answered by AI

What is the primary ambition of this clinical experiment?

"This trial intends to measure Axial Length (AL) in Month 3 as its primary outcome, with Undercorrected Visual Acuity at Baseline and Anterior Chamber Depth (ACD) at Month 1 acting as secondary objectives. To this end, participants will be subjected to line-by-line examinations of their visual acuity using the Early Treatment Diabetic Retinopathy Study logMAR E chart via standard illumination from 4 meters away throughout the 12 month duration of monitoring."

Answered by AI

Does this clinical trial have any open slots for enrollment?

"This clinical trial is not presently taking applicants, having been initially posted on September 22nd 2022 and most recently updated on November 2nd 2022. However, there are 98 other studies that can be accessed right now which accept participants."

Answered by AI

Who else is applying?

What state do they live in?
Texas
What site did they apply to?
University of California, San Francisco
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

What questions have other patients asked about this trial?

Has anyone damaged or lost their vision from these trials?
PatientReceived 2+ prior treatments
Recent research and studies
clinicaltrials.govStudy
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
2023. "Efficacy of Repeated Low-level Red-light Therapy in Myopia Control". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05606237.
All > Myopia
~52 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top